Please wait
0001815442424B5EX-FILING FEES 0001815442 2024-08-19 2024-08-19 0001815442 1 2024-08-19 2024-08-19 0001815442 2 2024-08-19 2024-08-19 xbrli:pure iso4217:USD xbrli:shares
Exhibit 107
Calculation of Filing Fee Tables
S-3
(Form Type)
Kymera Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
 
                         
     Security
Type		   Security
Class Title		   Fee
Calculation
or Carry
Forward
Rule		   Amount
Registered		   Proposed
Maximum
Offering
Price Per
Unit		   Maximum
Aggregate
Offering Price		   Fee Rate   Amount of
Registration
Fee
(1)
   Carry
Forward
Form
Type		   Carry
Forward
File
Number		   Carry
Forward
Initial
effective
date		   Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
                         
Fees to Be
Paid
   Equity   Common stock, $0.0001 per share   457(r)   6,349,692
(2)
   $40.75   $258,749,949   0.00014760   $38,191.50          
                         
Fees to Be
Paid
   Equity  
Pre-funded
warrants to purchase common stock		   457(r)   3,519,159   $40.75
(3)
   —
(3)
   0.00014760   —
(3)
          
                         
Fees
Previously Paid
   —   —   —   —   —   —     —          
 
Carry Forward Securities
                         
Carry
Forward Securities
   —   —   —   —     —       —   —   —   —
                   
    Total Offering Amounts      $258,749,949     $38,191.50          
                   
    Total Fees Previously Paid          —          
                   
    Total Fee Offsets         
—
          
                   
    Net Fee Due                $38,191.50                
  (1)
Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable in connection with the offering pursuant to this prospectus supplement has been paid in accordance with Rule 456(b) under the Securities Act, and represents deferred payment of the registration fees in connection with the registrant’s Registration Statement
on Form S-3ASR (File No. 333-259955).
 
  (2)
Includes 828,220 shares of common stock that the underwriters have an option to purchase and 3,519,159 shares of common stock that are issuable upon the exercise of the
pre-funded
warrants referenced below.
 
  (3)
Represents the sum of the offering price of $40.7499 per
pre-funded
warrant and the exercise price of $0.0001 per share issuable pursuant to the
pre-funded
warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the
pre-funded
warrants.